Skip to content

A Pilot- and Feasibility Trial of the EHealth Tool My COPD for People with COPD

A Randomized Controlled Pilot- and Feasibility Trial of the EHealth Tool My COPD, to Evaluate User Satisfaction, Reach and Safety in People with Chronic Obstructive Pulmonary Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05086341
Acronym
My COPD
Enrollment
22
Registered
2021-10-20
Start date
2021-11-05
Completion date
2023-10-01
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Telemedicine, Telerehabilitation, eHealth, Participatory, Exercise

Brief summary

The aim of this multi-center, randomized controlled pilot- and feasibility trial is to evaluate the user satisfaction, reach and safety of My COPD, a novel eHealth tool for remote delivery of evidence-based treatment targeting people with chronic obstructive pulmonary disease (COPD). In addition, the investigators aim to collect and synthesize data on clinical outcome measures to inform the sample size estimation of a later, definitive trial.

Detailed description

Chronic obstructive pulmonary disease (COPD) is one of the most common non-communicable (chronic) diseases, leading to significant increased risk of morbidity and mortality. Pulmonary rehabilitation is a comprehensive intervention, including but not limited to physical exercise, education and behavioral change. Conclusive evidence supports the provision of pulmonary rehabilitation in adults with COPD, which benefits exercise tolerance, physical activity, health-related quality of life, health care use, and survival. However, access to pulmonary rehabilitation needs to be increased, which has recently been highlighted as a top priority by leading experts in the area. To increase access to evidence-based treatment for people with COPD this research group has developed a novel eHealth tool, My COPD, in co-creation with intended end-users to meet requirements and needs of adults with COPD and health care providers. My COPD includes components to promote physical exercise, education and behavioral change, for example, information on disease management and treatment, symptom diary, an individualized physical exercise and activity plan, support from physiotherapist as well as self-management strategies. My COPD will be available on a nation-wide platform for internet-based support- and treatment programs that regional health care regions throughout Sweden offers. The research aim of this trial is to explore the users' satisfaction, reach and safety of My COPD, and to collect and synthesize data on clinical outcome measures to inform the sample size estimation of a later definitive trial. For this purpose, the investigators will conduct a multi-center, parallel-group randomized controlled pilot- and feasibility trial, with usual care as comparison group (control), for the duration of 12 weeks. In total, 30 adults with stable COPD will be recruited from hospitals and primary care centers located in public health regions in central (Region Stockholm) and northern (Region Västerbotten) Sweden. All participants will be invited to complete an initial screening and baseline assessment before the randomization and intervention commences. Descriptive baseline assessments that will be collected include assessment of pulmonary function (spirometry), while having usual bronchodilator therapy according to guidelines. Anthropometric data collected will include age, sex, height, weight, and body mass index. Further data that will be collected include information on smoking status, education, and co-morbidities and medications that may influence physical capacity or activity. At completion of informed consent, enrolment and baseline assessment procedures, participants will be randomized to either the intervention group (My COPD) or control group (usual care). Randomization will be conducted using opaque envelopes, and administered by a researcher not involved in the assessment procedures, thus, ensuring concealed allocation. Participants will be randomized to the intervention (My COPD) and control group (usual care) group, using a 2:1 allocation ratio and stratified by sex and center. Before and after the 12-week intervention assessments of exercise capacity, balance, level of physical activity, health related quality of life, COPD related symptoms, health economics will be conducted in all participants. During the intervention, data on exercise intensity, adverse events, adherence and progression will be collected from participants in the intervention group via My COPD. At intervention completion the user satisfaction of participants and health care professionals in the intervention group will be assessed. Participants in both groups will be asked to describe their COPD-related health care contacts during the study period. Physiotherapists, blinded to group allocation and previous test results, will conduct assessments.

Interventions

DEVICEMy COPD

In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.

Sponsors

Karolinska Institutet
CollaboratorOTHER
Umeå University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Parallel-group, randomized controlled pilot- and feasibility trial, 2:1 (I:C) randomization.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* a confirmed diagnosis of COPD

Exclusion criteria

* inability to read and understand Swedish * severe comorbidity that can be considered as the main contributing factor for limitation in physical activity. In case of an exacerbation, the participant has to wait six weeks from the start of pharmacological treatment before being eligible in the study.

Design outcomes

Primary

MeasureTime frameDescription
User satisfaction12-week follow-up (end of intervention)The mHealth App Usability Questionnaire (MAUQ) for patients, and health care staff, with score ranging 21-147 (higher score indicating better usability)

Secondary

MeasureTime frameDescription
COPD related symptomsBaseline and 12-week follow-up.The Modified Medical Research Council dyspnea scale (mMRC), with score ranging 0-4 (higher score indicating more symptoms)
Health related quality of life (HrQoL)Baseline and 12-week follow-upThe St Georges Respiratory Questionnaire (SGRQ), with score ranging from 0-100 (higher score indicating more limitation)
Physical capacityBaseline and 12-week follow-upThe 6 minute walk test (6MWT) (distance in meters)
Level of physical activityAccelerometer wear (7 days prior to intervention commencement) and at 12-week follow-upAccelerometer (Minimod, McRoberts®, NL) (steps, time in activity/inactivity)
Health economicsBaseline and 12-week follow-upThe EQ-5D to estimate change in quality-adjusted-life-years (QALYs), with score ranging 0-100 (higher score indicating better health)

Other

MeasureTime frameDescription
Exercise intensityDuring the 12-week interventionThe Borg CR-10, with a score ranging 0-10 (higher score indicating higher intensity)
Adverse eventsDuring the 12-week interventionFrequency and severity
Progression of exercisesDuring the 12-week interventionFrequency of completed exercise levels
AdherenceDuring the 12-week interventionFrequency of completed exercise sessions/activities

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026